Structure Therapeutics (NASDAQ:GPCR) Research Coverage Started at JPMorgan Chase & Co.

JPMorgan Chase & Co. initiated coverage on shares of Structure Therapeutics (NASDAQ:GPCR) in a research report released on Tuesday morning, MarketBeat reports. The brokerage issued an overweight rating and a $65.00 price objective on the stock.

GPCR has been the subject of a number of other research reports. Cantor Fitzgerald reiterated an overweight rating and issued a $65.00 target price on shares of Structure Therapeutics in a research report on Friday, May 3rd. JMP Securities reaffirmed a market outperform rating and set a $91.00 price objective on shares of Structure Therapeutics in a research note on Friday, May 10th. Finally, Lifesci Capital reaffirmed an outperform rating on shares of Structure Therapeutics in a research note on Tuesday, February 27th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of Buy and an average price target of $83.13.

Structure Therapeutics Stock Up 5.3 %

GPCR stock opened at $38.32 on Tuesday. Structure Therapeutics has a fifty-two week low of $25.43 and a fifty-two week high of $75.02. The firm’s 50-day simple moving average is $38.79 and its 200 day simple moving average is $43.84. The stock has a market cap of $1.79 billion and a PE ratio of -49.77.

Structure Therapeutics (NASDAQ:GPCR) last announced its earnings results on Friday, March 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.04. Equities analysts forecast that Structure Therapeutics will post -0.94 EPS for the current fiscal year.

Institutional Trading of Structure Therapeutics

A number of hedge funds have recently made changes to their positions in GPCR. Picton Mahoney Asset Management purchased a new stake in shares of Structure Therapeutics in the third quarter worth approximately $116,000. Sectoral Asset Management Inc. bought a new position in Structure Therapeutics during the fourth quarter valued at approximately $139,000. ADAR1 Capital Management LLC bought a new position in Structure Therapeutics during the fourth quarter valued at approximately $163,000. China Universal Asset Management Co. Ltd. raised its position in Structure Therapeutics by 208.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,349 shares of the company’s stock valued at $177,000 after acquiring an additional 2,939 shares in the last quarter. Finally, Washington University bought a new position in Structure Therapeutics during the third quarter valued at approximately $215,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.